EFB Section on Medicines Development participate in the EFPIA lead InnoMed FP6 Integrated Project
The integrated project is addressing the 3rd call for the FP6 programme under PRIORITY 1: Life Sciences, Genomics and Biotechnology for Health. The Consortium is lead by EFPIA (The European Federation of Pharmaceutical Industries and Associations). The proposal is addressing the call LSH-2004-1.2.1-1: New approaches for accelerated development of new, safe and more effective medicines.
The InnoMed Integrated Project
The 6th Framework Programme InnoMed Integrated Project research project can be considered a pilot project for the Innovative Medicines Initiative (IMI), which aims to improve the drug development process through a series of public-private collaborations for earlier and better prediction of drug safety and efficacy. IMI is part of the European Commission’s proposal for the 7th Framework Programme on Research and Technological Development.Within InnoMed 16 biopharmaceutical companies are collaborating with 13 Universities and 7 small and medium-sized enterprises (SMEs) to address some of the biggest bottlenecks in the development of new medicines. InnoMed consists of two separate scientific projects, PredTox and AddNeuroMed.
PredToxAims at studying toxicology of new treatments at an early phase. This involves the construction and delivery of an integrated database populated with data from in vivo experiments of compounds with known toxicity profile. It will include traditional endpoints supplemented with information from newer techniques i.e. transcriptomics, metabonomics and proteomics. This will among other things demonstrate how the different pharmaceutical companies can share scientific information between themselves, academia and biotechs in order to implement the application of new tools to aid decision making in Preclinical Safety. To date all participants (15 Companies, 2 SMEs and 3 Universities) have agreed on the overall protocol and selected 16 compounds for evaluation, including 2 reference compounds. In vivo experiments will be accomplished before the year end 2006.
Webpage: More information about the PredTox project, www.innomed-predtox.com
AddNeuroMed
Is using the consortium’s expertise in analytical techniques, pre-clinical and clinical development to provide technologies to
facilitate and accelerate the delivery of safe and effective medicines whist addressing the issues of:
The project is aimed specifically at the discovery and validation of new markers for diagnostics, disease progression and therapeutic
efficacy, and may lead to improved animal models of AD as a byproduct. The progression from in vitro to animal testing to the clinic
is a blueprint for how similar approaches might be undertaken for other major diseases. The details are specific for Alzheimer
Disease, but the approach can also be applied to other indications.
Post doctoral researchers and clinical staff have been recruited, animal studies in mice, rat and drosophila are in progress and
the first patients have been recruited
Webpage: More information about the AddNeuroMed project, www.innomed-addneuromed.com
For further information, please contact Berit Albrechtsen (email: Berit Albrechtsen)